You know me well enough to know that, as I have often said, "To me, part of the reason for investing here has always been a stock play, such they executed previously DBA Kalobios."
When management provides guidance that the Liquidating Trustee has sole discretion to declare a Distribution, but that no distribution is expected to existing equity holders, I have to acknowledge that. But I think you'd have to be dumber than a fencepost to believe that. The judge would not have approved the amended Asset Purchase Agreement, without the expectation that Humanigen was going to reach specified Milestone Events, which are triggered by some sort of Regulatory authorization or approval. Reuniting the share structure with the Intellectual Property rights is, for people like our management, a relatively simple task to merge Humanigen and Taran. I think it could be similar to what we saw from InhibRx.
"Prior to the closing of the acquisition, Inhibrx completed the spin-off of Inhibrx Biosciences, Inc. (“Inhibrx Biosciences”), distributing 92% of Inhibrx Biosciences’s shares to holders of shares of Inhibrx common stock as of May 17, 2024. Inhibrx Biosciences, which was a wholly owned subsidiary of Inhibrx prior to the distribution, acquired all of the assets of Inhibrx not related to SAR447537, which include INBRX-109 and INBRX-1061, as well as all Inhibrx employees, pursuant to an internal reorganization. Inhibrx continues to own the remaining 8% of Inhibrix Biosciences following the completion of the transactions. Inhibrx Biosciences began trading on the NASDAQ Global Market on May 30, 2024, under the ticker “INXB” and, beginning on May 31, 2024, will trade under the ticker “INBX”.
There is no way that I see management proceeding without the shareholders. Identifying the existing equity holders will be determined by our Transfer Agent, rather than the DTC. I expect that journal to reflect a float that is 192% of our OS, and the Distribution will force a buy-in of all the shares in our market.
The forced buy-in, news regarding lenzilumab's safety and efficacy for CMML, as well as aGvHD, lenzilumab's performance in improving CAR-T and enhancing non-mRNA covid vaccines, plus news regarding Sanofi and Novavax, regarding not only licensing deals, but additional partnership status updates, will rock our market, and hopefully allow me to make some sells Monday.
The unfolding truth of excess deaths and Serious Adverse Events from mRNA vaccines will result in demand for lenz far surpassing the $1B revenue goal initially targeted by the company. I suspect there will be a market from infected, non-hospitalized patients with elevated CPR levels. Lenz demonstrated an 8-fold improvement in treating patients with <41mg/L of CRP.
I just don't think we have ever been stronger, despite appearances, which can change in the blink of an eye.
News 
Market Data 
Discover 
